Loading...
FDA approval of docetaxel in 2004 provided clinicians who manage advanced prostate cancer with a drug that effectively reduced disease-related symptoms and modestly improved survival. However, the optimal management of patients with advanced disease after docetaxel treatment is unclear. As a result, clinicians have used a range of options, including retreatment with docetaxel, use of other chemotherapeutic agents (such as mitoxantrone), and additional hormonal maneuvers with agents (such as ketoconazole).
Now, a group of international investigators has conducted a pharmaceutical company–sponsored, phase III trial of cabazitaxel (a tubulin-binding taxane with preclinical activity in docetaxel- and paclitaxel-resistant cell lines) versus mitox…